Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Provider notice of LAI buprenorphine funding program
The long-acting injectable (LAI) buprenorphine funding program is for small providers treating Apple Health clients and the uninsured.
Are you a small provider who needs help purchasing LAI buprenorphine for your patients?
The Legislature appropriated $3 million of the opioid abatement settlement funds to HCA to increase access to long-acting injectable (LAI) buprenorphine products during fiscal year 2024.
The purpose of this program is to allow small providers to have LAI buprenorphine stocked in the clinic when a patient with an opioid use disorder comes in, and to ensure that small providers have funds to continue to administer LAI buprenorphine to patients after this funding ends. Small providers are defined as a clinic with 5 or fewer licensed prescribers that prescribe Sublocade or Brixadi, not owned or operated by a hospital or carceral facility.
This program ends on June 30, 2025, or when funding is exhausted, whichever occurs first.
To learn more about this program see the FAQ document.